For Industry

Available technologies

Clear search
Novel phage/AAV delivery vector for gene therapy, medical imaging and vaccine delivery

The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.

Novel protein fragment of von Willebrand’s factor for treating VWD and haemophilia A

Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.

PEGylated nanomaterials

Functionalised graphene for use as a nucleant

Immunotherapy for IBD

Lactobacillus ST peptide for therapeutic use against inflammatory bowel disease

Novel treatment for Huntington’s Disease

Dr Mark Isalan – Reader in Gene Network Engineering at Imperial College London – and collaborators have developed a novel gene therapy for Huntington’s Disease that leverages zinc finger protein technology.

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London